Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1999;85:515-523

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massaeli, H.
Right arrow Articles by Pierce, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massaeli, H.
Right arrow Articles by Pierce, G. N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Related Collections
Right arrow Pathophysiology
Right arrow Smooth muscle proliferation and differentiation
Right arrow Lipid and lipoprotein metabolism
(Circulation Research. 1999;85:515-523.)
© 1999 American Heart Association, Inc.


Cellular Biology

Chronic Exposure of Smooth Muscle Cells to Minimally Oxidized LDL Results in Depressed Inositol 1,4,5-Trisphosphate Receptor Density and Ca2+ Transients

Hamid Massaeli, J. Alejandro Austria, Grant N. Pierce

From the Division of Stroke and Vascular Disease, St. Boniface General Hospital Research Centre, and Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Correspondence to Grant N. Pierce, PhD, FACC, Director, Division of Stroke and Vascular Disease, St. Boniface General Hospital Research Centre, 351 Tache Ave, Winnipeg, Manitoba, Canada R2H 2A6. E-mail pierce{at}sbrc.umanitoba.ca


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Oxidized LDL (oxLDL) (0.1 mg/mL) increased [Ca2+]i in vascular smooth muscle cells (VSMCs) within 5 to 10 seconds of incubation. This increase was mediated via an inositol 1,4,5-trisphosphate (IP3)-dependent release of Ca2+ from the sarcoplasmic reticulum. However, atherosclerosis is a gradual process in which VSMCs are more likely exposed to low concentrations of oxLDL over extended periods rather than acute exposures. It is very possible, therefore, that lower [oxLDL] and longer exposure times may induce a very different response with regard to regulation of [Ca2+]i. VSMCs were incubated with 4- to 100-fold lower [oxLDL] for up to 6 days. The conditions were not cytotoxic. Basal [Ca2+]i was not altered. Surprisingly, however, after chronic exposure to oxLDL, a brief addition of oxLDL (0.1 mg/mL) or norepinephrine failed to elicit the expected rise in Ca2+i. Because the acute effects of oxLDL on control cells were mediated through an IP3-dependent pathway, we investigated the integrity of the VSMC IP3 receptors. Immunocytochemical analysis and Western blots revealed a depression in the density of IP3 receptors after chronic exposure of VSMCs to oxLDL. These changes in IP3 receptors have significance under atherosclerotic conditions as well. Immunocytochemical analysis revealed a decrease in IP3 receptor density in the medial layer under atherosclerotic plaques in situ. Our data, therefore, demonstrate a striking difference between the acute and chronic effects of oxLDL on VSMC calcium. Whereas acute exposure to oxLDL stimulates [Ca2+]i, chronic exposure results in depressed Ca2+ transients, apparently through a decrease in IP3 receptor density. These changes have functional implications for the atherosclerotic vessel in vivo, and our data implicates oxLDL in this process.


Key Words: oxidized LDL • vascular smooth muscle cell • atherosclerosis • Ca2+ • sarcoplasmic reticulum


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The initiation and development of atherosclerotic lesions are correlated with circulating cholesterol and LDL levels.1 Oxidative modification of LDL (oxLDL) enhances its atherosclerotic properties and may represent the first step in the initiation of atherosclerosis.1 2 OxLDL can induce a massive deposition of cholesterol esters in vascular smooth muscle cells (VSMCs) and macrophages to transform them into foam cells within the atherosclerotic lesion.3 4 However, the precise mechanism whereby oxLDL initiates and propagates the atherosclerotic lesion is still not known.

The current concept regarding the development of atherosclerosis is dominated by the assumption that the accumulation of lipids is the primary risk factor. Less research attention has been directed toward the role of calcium in this process. However, a significant increase in cellular calcium has been identified in atherosclerotic vessels.5 The increase in cell calcium is thought to be involved in several important processes associated with atherosclerosis. These include abnormalities in VSMC contraction and proliferation, excessive secretion of extracellular matrix proteins (such as collagen, elastin, and proteoglycans), secretion of chemoattractants and growth factors, and platelet aggregation.6 7

Recently, several studies have demonstrated that an acute administration of oxLDL generates a Ca2+ transient in different cell types (for review, see Reference 88 ). The ability for a single exposure of oxLDL to generate a rapid Ca2+ transient was suggested to be important in atherosclerosis. However, this stimulatory effect of an acute exposure of oxLDL on VSMC [Ca2+]i appears to be in conflict with many studies that have shown arterial smooth muscle to be unresponsive to a variety of vasoactive agents under atherosclerotic conditions.9 10 11 12 The discrepancy may be due to the time of exposure of VSMCs to oxLDL. Atherosclerosis is a relatively slow, gradual process. It may be more relevant to this disease state to selectively examine the cellular effects of oxLDL, an important atherosclerotic factor, over a period of time. The purpose of this study, therefore, was to determine the effect of oxLDL on [Ca2+]i in VSMCs that have been chronically incubated with low [oxLDL]. Surprisingly, our results demonstrate that cells become nonresponsive to oxLDL after they are incubated for extended periods of time with oxLDL. This is accompanied by a striking change in inositol 1,4,5-trisphosphate (IP3) receptor density in VSMCs. This change is also observed in situ in the atherosclerotic plaques obtained from cholesterol-fed rabbits.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
LDL Isolation and Oxidation
LDL (density 1.019 to 1.063 g/mL) was prepared by sequential ultracentrifugation.13 EDTA (0.1 mmol/L) was added throughout the isolation to prevent oxidation of LDL. The LDL fraction was extensively dialyzed against 0.15 mol/L NaCl and 0.1 mmol/L EDTA (pH 7.4), sterile-filtered, and stored at 4°C. The protein content and cholesterol content (free and esterified) of LDL were measured as described.13 14 The absence of LDL oxidation during isolation or before its use in experiments was confirmed by an absence of malondialdehyde reactive products and oxidized cholesterol.13

The EDTA concentration in native LDL was reduced before LDL oxidation. Native LDL was diluted 10-fold in 150 mmol/L NaCl (pH 7.4) and oxidized by incubation with a solution of 50 µmol/L FeCl3 and 0.25 mmol/L ADP for 3 hours at 37°C. The extent of LDL oxidation was evaluated by (1) measurement of thiobarbituric acid reactive substances,13 15 (2) electrophoretic mobility on agarose gels (using the Chiron Diagnostic Lipoprotein System), and (3) measurement of {alpha}-tocopherol content by high-performance liquid chromatography.16

Vascular Smooth Muscle Cells
An explant technique was used to generate primary cultures of VSMCs from normal rabbit thoracic aorta.17 The aorta from a male New Zealand White rabbit (2.5 to 3 kg body weight) was isolated and cleaned of excess fat and connective tissue. The aorta was cut into 2- to 3-mm sections and transferred to a culture dish with growth medium (20% FBS in DMEM) and 5% antibiotic antimycotic (Gibco BRL). The explants were incubated in a humidified incubator equilibrated with 5% CO2 and maintained at 37°C. Initial migration of VSMCs was observed within the first 6 days. After 7 days of migration, these explants were transferred to a new culture dish for further migration. VSMCs from the second phase of migration were used in our experiments. To induce differentiation, VSMCs were placed (for 5 to 6 days) in a serum-free medium as described.18

Chronic Treatment of VSMCs With oxLDL
VSMCs used in our experimental protocol were from either the first or second passage. The cells were serum-starved for 6 days before exposure to oxLDL. In chronic experiments, VSMCs were exposed for a period of 6 days to different concentrations of freshly prepared oxLDL (0.001 to 0.025 mg cholesterol/mL LDL). The medium containing freshly oxidized LDL was added daily to the cultured cells. The control cells were also kept in culture for the same length of time as the treated cells. The cytotoxicity of different concentrations of oxLDL was assessed by two tests: (1) lactate dehydrogenase (LDH) released into the culture medium19 and (2) ethidium homodimer staining of cell nuclei (Viability/Cytotoxicity Assay Kit, Molecular Probes).

IP3 Content
VSMCs with and without treatment with oxLDL were washed with ice-cold PBS, then scraped down and homogenized. This homogenate was used to measure D-myo-inositol 1,4,5-trisphosphate (IP3) content in VSMCs with a radioisotopic assay kit (Amersham).

Immunocytochemistry
VSMC phenotype was identified using monoclonal antibodies against smooth muscle {alpha}-actin, myosin, and caldesmon (Sigma-Aldrich). For the identification of IP3 receptors within VSMCs, quiescent cells were fixed and incubated with monoclonal anti-IP3 receptor antibodies that recognize all 3 types of IP3 receptors (ie, type I, II, and III) (Calbiochem). These cells were further incubated with a secondary antibody conjugated to FITC. The fluorescent images were obtained with a Bio-Rad MRC-600 confocal system.

Immunohistochemistry
The aortas from both control and 0.5% cholesterol-fed (12- to 14-week diet) male New Zealand White rabbits were cut into 5-mm sections and placed in a mold covered with O.C.T. embedding compound (Sakura Finetek, Torrance, Calif). These molds were frozen and cut into 7-µm sections using a Leitz 1720 Cryostat. Before use, these slides were fixed in 1:1 solution of acetone and methanol (-20°C) for 15 minutes. These sections were then blocked with 5% skim milk and incubated with monoclonal anti-IP3 receptor antibody (1:100) overnight at 4°C. The aortic sections were then incubated with anti-mouse IgG biotinylated whole antibody (from goat) (1:20) followed by streptavidin conjugated to Texas Red (1:20) (Amersham). Rabbits were obtained from local suppliers and maintained in the Animal Care Facility at St. Boniface Hospital Research Centre under the guidelines of the Canadian Council on Animal Care.

Western Blotting
After treatment of VSMCs with oxLDL, cells were lysed with lysis buffer (1% SDS, 100 mmol/L NaCl, 62.5 mmol/L Tris-HCl [pH 7.6], 1 mmol/L PMSF, and 10 µg/mL leupeptin). Cell extracts were denatured with sample buffer (62.5 mmol/L Tris-HCl, 1% SDS, 10% glycerol, 0.01% bromophenol blue, and 20 µg/mL ß-mercaptoethanol) at 100°C for 5 minutes. The samples were separated on a 6% SDS polyacrylamide gel and transferred electrophoretically onto a polyvinylidene difluoride membrane before incubating with a polyclonal anti-IP3 receptor antibody (Chemicon International Inc). The blots were incubated with HRP-conjugated goat anti-rabbit IgG. The IP3 receptor was detected with Pierce Super Signal detection system.

Calcium Measurements
Measurement of [Ca]i in a single cell was carried out using a Spex spectrofluorometer, as described in detail previously.13 20 Cultured VSMCs were loaded with 2 µmol/L fura-2 for 20 minutes at 22°C in a Krebs-Henseleit buffer (in mmol/L: NaCl 120, NaHCO3 25, KCl 4.8, KH2PO4 1.2, MgSO4 1.25, CaCl2 1.8, and dextrose 8.6). The fluorescent intensities of fura-2, which reflects bound and unbound calcium, were determined by exciting the cell at 340 and 380 nm and recording emission at 505 nm. The maximum and minimum fluorescence signals were obtained by adding 10 µmol/L 4-Bromo-A23187 and 5 mmol/L EGTA, respectively, at the end of the experiment to calibrate the signal with the [Ca2+]i.21

Statistical Analysis
Data were expressed as mean±SE. The statistical comparisons were made using one-way analysis of variance, followed by the Student-Newman-Keuls test for multiple comparison. Differences between means were considered significant at P<0.05.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Acute Exposure of VSMCs to oxLDL
What Is the Mechanism Responsible for the Enhanced Ca2+ Transient After Acute Exposure of VSMCs to oxLDL?
LDL was oxidized with an Fe-ADP free radical generating system.13 This LDL exhibited characteristics consistent with limited oxidation. The Fe-ADP–treated LDL exhibited a modest increase in electrophoretic mobility in comparison to native LDL, a limited 33% increase in malondialdehyde products indicative of lipid peroxidation and a 21% decrease in LDL vitamin E content (from 12.7 mg/L before oxidation to 10.1 mg/L after exposure to the Fe-ADP). These characteristics are consistent with the generation of a minimally modified oxLDL.

We first examined the effects of a concentration of oxLDL frequently used in other studies for the cellular effects of oxLDL.8 As shown in Figure 1Down, 0.1 mg/mL oxLDL caused a rapid increase in Ca2+i. The peak increase in Ca2+i was observed within 5 to 10 seconds of exposure to oxLDL. The Fe-ADP free radical generating system did not have any effect on Ca2+i by itself. Native LDL elicited either no change or a modest increase in the Ca2+ transient in VSMCs (data not shown). Removing oxLDL from the solution bathing the VSMCs (Figure 1ADown) could eliminate the effects of oxLDL on Ca2+i. The increase in [Ca2+]i induced by 0.1 mg/mL oxLDL was also observed in a calcium-free solution (Figure 1BDown). Therefore, the increase in Ca2+i induced by oxLDL likely resulted from a release of Ca2+ from the sarcoplasmic reticulum (SR). This increase in [Ca2+]i in response to oxLDL occurred in all cells irrespective of the basal [Ca2+]i.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 1. Representative results demonstrating the acute effect of oxLDL on Ca2+i in a single VSMC. A, OxLDL (0.1 mg cholesterol/mL) induced a rapid increase in Ca2+i. The resting calcium level was reestablished by removing oxLDL from the solution bathing the cell. B, OxLDL (0.1 mg cholesterol/mL) induced a rapid increase in Ca2+i in a calcium-free solution.

Ca2+ release from the SR can occur via an IP3 signaling mechanism.22 Therefore, oxLDL was tested for its capacity to increase VSMC IP3 levels. The basal IP3 concentration was {approx}20 pmol/mg protein. The IP3 levels in VSMCs acutely exposed to 0.1 mg/mL oxLDL for 20 seconds increased by {approx}5 fold (Figure 2Down). To further identify the potential signaling pathway through which oxLDL acted to cause a release of calcium from the SR, we used NCDC, which disrupts the phosphatidylinositol cascade in the cell via an inhibition of phospholipase C.23 In 5 separate cell experiments, two cells exhibited a small, delayed response to oxLDL in the presence of NCDC (as shown in one representative experiment in Figure 3Down). NCDC-treated cells were completely unresponsive in 3 other cases. Incubation of VSMCs with 50 µmol/mL NCDC blocked IP3 formation even after stimulation with 0.1 mg/mL oxLDL (Figure 2Down).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. Effect of chronic exposure to oxLDL on intracellular IP3. VSMCs were treated with ±0.1 mg/mL oxLDL and in the presence or absence of 50 µmol/mL NCDC (phospholipase C inhibitor), and IP3 concentration was quantified 20 seconds after exposure. Cells that were chronically treated with oxLDL (0.025 mg/mL for 6 days) were then exposed to 0.1 mg/mL oxLDL, and the IP3 was quantitated as above. The IP3 values were adjusted to milligrams of protein content. The values presented are mean±SE of 3 to 6 different experiments. **P<0.001 vs control.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Blunting of the effect of oxLDL on VSMC Ca2+i by NCDC. A, Effect of 0.1 mg cholesterol/mL oxLDL on a single cell. B, VSMCs were pretreated with 50 µmol/L NCDC for 30 minutes, then stimulated with 0.1 mg cholesterol/mL oxLDL. This is a representative recording from one cell.

Chronic Exposure of VSMCs to oxLDL
What Effect Does Chronic Exposure of VSMCs to oxLDL Have on Cell Integrity?
Although VSMCs were acutely responsive to oxLDL, these cells may have a different response after extended exposure to oxLDL in culture. VSMCs were treated for up to 6 days with concentrations that were up to 100-fold lower than those previously tested in the acute experiments. The medium was changed daily. This medium contained freshly prepared oxLDL. Control cells were maintained for the same amount of time in an identical medium except for the addition of oxLDL.

OxLDL has a cytotoxic effect on cultured cells.24 Therefore, it was important to assess the effect of these concentrations of oxLDL on the viability of VSMCs. The viability of VSMCs was tested using the Live/Dead assay and also examined with LDH release from the cells. Incubation of cells with 0.025 mg/mL oxLDL over a 6-day period did not induce a cytotoxic effect as determined by the Live/Dead assay, nor was there a significant release of LDH into the medium in comparison to control untreated cells (data not shown). Subsequent experiments, therefore, were undertaken at [oxLDL]<=0.025 mg/mL.

Will Chronic Exposure of VSMCs to oxLDL Alter Basal [Ca2+]?
A small proportion of the VSMCs incubated chronically with oxLDL exhibited a change in cell morphology to foam cells. These cells were not the focus of our study. Instead, we chose to investigate [Ca2+] in cells that maintained the long, spindle shape that is typical of VSMCs. Cells were incubated with 0.001 to 0.025 mg cholesterol/mL for up to 6 days. The basal [Ca2+] was not significantly changed among the different experimental groups (P>0.05). [Ca2+]i was 182±22 nmol/L (n=24), 154±14 nmol/L (n=32), and 219±19 nmol/L (n=22), for cells treated with 0, 0.005, and 0.025 mg/mL oxLDL, respectively.

Will Chronic Exposure to oxLDL Alter Cellular Ca2+ Transients in Response to Subsequent Stimulation by oxLDL?
VSMCs were incubated with oxLDL for 6 days, then washed and examined for their ability to respond with an increase in [Ca2+]i to an acute application of 0.1 mg/mL oxLDL. The extended treatment of VSMCs with different [oxLDL] had a pronounced effect on Ca2+i regulation. Some, but not all, of the VSMCs responded to oxLDL with an increase in Ca2+i. By examining the number of cells that responded to oxLDL with a rise in [Ca2+]i in comparison to the total number of cells tested in each experimental group, a responder ratio was obtained (Figure 4Down). Less than 10% of VSMCs treated with higher [oxLDL] (0.01 and 0.025 mg/mL) for 6 days subsequently responded to 0.1 mg/mL oxLDL with a change in Ca2+i. A relatively low [oxLDL] (0.005 mg/mL) led to a 40% decrease in responder ratio compared with control. There was no difference in responder ratio between control VSMCs and the cells chronically treated with 0.001 mg/mL oxLDL.



View larger version (59K):
[in this window]
[in a new window]
 
Figure 4. Effect of chronic exposure to oxLDL on [Ca2+]i. Responder ratio of VSMC Ca2+ to oxLDL stimulation. VSMCs were exposed to different concentrations of oxLDL (0.001 to 0.025 mg/mL) for 6 days. These cells were then stimulated with 0.1 mg cholesterol/mL oxLDL. The percentage of cells that responded to oxLDL by an increase in [Ca2+]i within 1 minute after the application of oxLDL is shown. The values represent 4 to 15 different experiments for each group.

The Ca2+ transient was altered even in the cells that did respond to oxLDL. As shown in representative recordings from single cells (Figure 5Down), cells responded immediately as a result of acute stimulation with 0.1 mg/mL oxLDL; however, the peak response was reduced as the concentration of oxLDL used in the chronic incubation period increased. VSMCs that were chronically incubated with higher [oxLDL] (from 0.01 to 0.025 mg/mL) failed to respond to the calcium mobilizing effect of oxLDL. Data from a large number of separate experiments were compiled together for analysis (TableDown). The chronic incubation of VSMCs for 6 days at concentrations of oxLDL as low as 0.005 mg/mL resulted in a significant blunting of the subsequent effect of oxLDL on Ca2+i transients. However, it is also interesting to note that the lowest [oxLDL] tested (0.001 mg/mL) induced a Ca2+ transient with a half-time that was approximately twice as long as the control cells (TableDown).



View larger version (31K):
[in this window]
[in a new window]
 
Figure 5. Effect of oxLDL on the [Ca2+]i transient. VSMCs were exposed to different concentrations of oxLDL as indicated for 6 days. The tracings are taken from representative cells showing the effect of 0.1 mg/mL oxLDL on the intracellular free calcium. Arrow indicates the addition of oxLDL.


View this table:
[in this window]
[in a new window]
 
Table 1. Percentage of Change in [Ca2+]i From Basal Level in Smooth Muscle Cells Chronically Exposed to oxLDL for 6 Days

To test whether oxLDL is responsible for the alteration in the Ca2+ transient, we used native LDL in the same chronic setting. VSMCs were treated for 6 days with different concentrations of native LDL (0.001 to 0.025 mg cholesterol/mL). These cells were then stimulated with 0.1 mg/mL oxLDL. All cells responded to oxLDL with a Ca2+ transient (data not shown).

To test the responsiveness of chronically treated cells to other agonists that target SR calcium release, we used norepinephrine ({alpha}-adrenergic agonist). Binding of norepinephrine to its {alpha}-adrenergic receptor will result in activation of phospholipase C, formation of IP3, and [Ca2+]i release from the SR. As shown in Figure 6Down, control VSMCs responded to norepinephrine with a rapid increase in [Ca2+]i, whereas VSMCs treated with 0.025 mg/mL oxLDL for 6 days failed to show an increase in [Ca2+]i after exposure to norepinephrine.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 6. Effect of norepinephrine on [Ca2+]i in VSMCs chronically treated with oxLDL. VSMCs were treated with ±0.025 mg/mL oxLDL for 6 days. These cells were then loaded with fura-2 as described in Materials and Methods. Norepinephrine (100 µmol/mL) was added to the cells as indicated by the arrow. The values are mean±SE of 4 different experiments. *P<0.05 vs basal [Ca2+].

What Is the Mechanism Responsible for the Chronic Effects of oxLDL on VSMC Ca2+?
VSMCs may have lost their capacity to respond to oxLDL with an increase in Ca2+i because of (1) a decrease in oxLDL binding to the cell surface or (2) an alteration in the intracellular signaling, which effected the increase in Ca2+i. Because the receptors that regulate oxLDL binding to the cell have not been fully characterized and because oxLDL may gain access to the cell through several different receptors, it is impossible to directly assess this first possibility.25 However, we could address the second possibility. As demonstrated previously (Figure 2Up), the acute effects of oxLDL on Ca2+i were likely due to an IP3-mediated release of Ca2+ from the SR. Therefore, it was reasonable to hypothesize that an extensive incubation of VSMCs with oxLDL resulted in a change in the IP3 signaling pathway. VSMCs were treated with 0.025 mg/mL oxLDL for 3 or 6 days. These cells were then fixed and treated with a monoclonal antibody against the IP3 receptor. This anti-IP3 antibody recognizes all 3 known isoforms of the IP3 receptor (type I, II, and III). However, because VSMCs contain 73% of type I IP3 receptors, the signal likely emanates mostly from type I IP3 receptors.26 Figure 7aDown through 7c represents results from control cells. These cells show a high expression of IP3 receptors in the periphery of the nuclei and throughout the cytoplasm. VSMCs that were treated with oxLDL for 3 days (Figure 7dDown through 7f) exhibited a small decrease in the density of IP3 receptors from control. However, a longer treatment period (6 days) led to a striking reduction in IP3 receptor density throughout cells (Figure 7gDown through 7i). This was quantitated by Western immunoblots. As shown in Figure 8Down, incubation of VSMCs for 6 days with 0.025 mg/mL oxLDL resulted in a significant decrease in IP3 receptor density. This defect in IP3 receptor density was accompanied by a depressed capacity to generate IP3 in cells chronically exposed to oxLDL (Figure 2Up). Thus, chronic exposure of VSMCs to oxLDL leads to a significant depression in IP3 signaling in the cells due to an attenuated generation of IP3 and a decrease in IP3 receptor density.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 7. Effect of extended exposure to oxLDL on IP3 receptor distribution in VSMCs. VSMCs were treated with 0.025 mg cholesterol/mL oxLDL for 0 (a through c), 3 (d through f), and 6 (g through i) days. These cells were then immunocytochemically stained for IP3 receptors. Images were collected using a Bio-Rad confocal microscope. All settings were kept constant for comparative reasons. The images were enhanced in size 1.4- to 1.6-fold.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 8. Effect of chronic exposure to oxLDL on IP3 receptor density in VSMCs as determined by Western blotting. VSMCs were treated with 0.025 mg cholesterol/mL oxLDL for 6 days. A, The polyclonal anti-IP3 receptor antibody recognizes a 260-kDa protein. B, Values from 4 different experiments were plotted as the percentage of change from control. *P<0.05 vs control (n=4).

Are the Changes in IP3 Receptor Density Found in Atherosclerotic Tissue In Situ?
The possibility exists that the cell culture conditions used may not mimic the in vivo situation in atherosclerosis. It is unknown whether vascular IP3 receptors are affected by atherosclerosis. Aortic tissue was removed from rabbits fed a 0.5% cholesterol-supplemented diet for 12 to 14 weeks. This tissue exhibited gross atherosclerotic plaques. Sections from these atherosclerotic aorta and control aorta were examined with immunohistochemical staining for changes in IP3 receptor density (Figure 9Down). IP3 receptors stained strongly in the medial section of control aorta (Figure 9ADown), whereas this staining was reduced in the medial section of atherosclerotic tissue (Figure 9BDown). This difference in IP3 receptor density was also observed in aortic sections that contained both plaque and an unaffected area (Figure 9CDown). As shown in Figure 9CDown, IP3 receptor density was higher in the medial layer of an area with no plaque, whereas the same medial layer below the plaque region exhibited a reduction in fluorescence intensity.



View larger version (48K):
[in this window]
[in a new window]
 
Figure 9. IP3 receptor density in the medial region of the aorta. Aortic tissue isolated from rabbits fed a control diet or a 0.5% cholesterol-supplemented diet. Sections (7 µm each) were prepared and incubated with anti-IP3 receptor antibody. A, Control aortic section. B, Atherosclerotic region of aorta from cholesterol-fed rabbit. C, Aorta from cholesterol-fed rabbit showing both plaque region and area with no plaque. Note that the strong IP3 receptor staining in the area devoid of plaque formation contrasts strongly with the poor receptor density in the plaque region even within the same section. d, Immunofluorescence exhibited by a section stained with preimmune sera. IEL indicates internal elastic lamina; M, medial layer or tunica media; and A, adventitial layer or tunica adventitia.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
Acute Effects of oxLDL
Our data demonstrate that the transient exposure of VSMCs to oxLDL results in an immediate rise in [Ca2+]i. OxLDL induced the Ca2+ transient through a phosphoinositide-mediated release of Ca2+ from intracellular stores located in the SR. This conclusion is supported by several observations. First, oxLDL was capable of generating an increase in intracellular IP3 levels. Second, a blocker of phospholipase C activity, NCDC, blunted the rise in intracellular IP3 and [Ca2+]i. Third, the effects of oxLDL on VSMC Ca2+ could be observed even in the absence of [Ca2+]o, and finally, the inactivation of SR function by prior treatment with ryanodine blocked the effects of oxLDL on VSMC Ca2+ (data not shown). The effects of oxLDL are related to the oxidized products generated within the LDL. Native LDL (when applied to the cells soon after isolation) induced either no change or extremely small increases in VSMC [Ca2+] (data not shown). Fe-ADP used at the same concentration had no effect on [Ca2+]i on its own.

Chronic Effects of oxLDL
The effects of oxLDL under acute exposure conditions contrast sharply with the effects of oxLDL after VSMCs have been chronically exposed to low [oxLDL]. Chronic exposure of VSMCs to oxLDL resulted in a loss in the capacity of oxLDL to initiate a Ca2+ transient. This alteration in Ca2+ transient was due to the oxidation of LDL, because native LDL in a similar chronic setting did not show any effect on the Ca2+ transient. The oxLDL preparation used in the present study was minimally modified, and the concentrations used were 10- to 100-fold below those used by many other investigations that have tested the effects of oxLDL on cell function.8 27 28 This reinforces the potency that small quantities of oxLDL have on cell function and emphasizes the potential pathological significance of the effects observed.

Many studies have implicated oxygen-derived free radicals and oxLDL in the atherosclerotic process.1 2 3 4 Are cells in the area of a developing plaque exposed to oxLDL for extended periods of time? No direct evidence is available; however, indirect evidence would support this contention. For example, the generation of autoantibodies to oxLDL strongly suggests that the oxLDL is present for extended periods of time in the body.29 30 Further, the autoantibody titers correlate with the severity of the plaque formation.30 These findings would suggest that the oxLDL must be elevated chronically. It is also likely that this oxLDL is trapped in the interstitial space and cells would be chronically exposed to it.1 Several other studies have demonstrated that [oxLDL] or its products increase within the plaque as the plaque advances in severity.31 32 These data do not prove that VSMCs or other vascular cells are in contact with oxLDL over extended periods of time, but it is a contention that would be entirely consistent with the general hypothesis of a role for oxLDL in the atherogenic process. Indeed, if one is to assign a role for oxLDL in atherosclerosis, it is far more difficult to argue that cells would be in contact with oxLDL for several minutes in vivo than the contention that cells in a developing atherogenic region are exposed chronically to oxLDL. Our data demonstrate that such conditions have important implications for VSMC function, and that these effects are strikingly different than those previously reported under acute exposure periods.

Several factors may be eliminated in the present study as contributory factors to the effects of oxLDL. For example, this was not due to a cytotoxic effect of the oxLDL. Furthermore, this was not due to a change in VSMC morphology to that of a foam cell. We purposefully examined cells that maintained the spindle-shape morphology that is typical of VSMCs. Interestingly, however, foam cells also failed to elicit a Ca2+ transient in response to any agonist tested (data not shown). This would suggest that oxLDL may induce a transitional change in VSMC function that precedes significant morphological changes.

We have identified one factor that may contribute to the inability of oxLDL to induce a Ca2+ transient after VSMCs have been chronically exposed to oxLDL. We have focused our work on the effects that oxLDL had on intracellular signaling. The present data strongly suggest that the mechanism responsible for the oxLDL-induced change in Ca2+ responsiveness within the VSMCs involves a lesion in IP3 signaling. Because oxLDL appeared to induce a release of Ca2+ from SR via an IP3-mediated mechanism under acute exposure conditions (Figures 1 through 3UpUpUp), it is reasonable to argue that the loss in IP3 receptors under chronic exposure conditions is at least partly responsible for the altered Ca2+ transients. Consistent with this hypothesis, we demonstrate for the first time that IP3 receptor density is strongly depressed in VSMCs exposed to oxLDL over time. We cannot rule out an alternative possibility that oxLDL binding to the VSMCs is depressed after chronic incubation periods. However, cellular lipid accumulation continues even in the presence of elevated [oxLDL].1 This would suggest that the cells have a limited capacity to downregulate oxLDL receptors and thereby control oxLDL interactions with the cell.1 33 Furthermore, the observation that another agonist (norepinephrine) that binds to a different surface receptor than oxLDL but initiates the same IP3 signaling pathway as oxLDL also is incapable of generating a Ca2+ transient argues strongly that the primary defect is the IP3 signaling.

The mechanism responsible for the downregulation in IP3 receptors is unclear. However, Wojcikiewicz et al34 demonstrated a downregulation in IP3 receptor type I as a result of prolonged exposure of human neuroblastoma to carbachol (a muscarinic agonist). They suggested that persistent elevation in [Ca2+]i may be the mechanism leading to downregulation of these receptors. A similar downregulation of IP3 receptors and desensitization of Ca2+ release were also observed in rat A7r5 aortic smooth muscle cells as the result of chronic stimulation with vasopressin.35 Their data and other studies suggested that this downregulation was due to proteasomal degradation and accelerated proteolysis.35 36 Ultimately, IP3 generation was also depressed in VSMCs chronically treated with oxLDL (Figure 2Up). This would argue against an association of elevated [IP3]i with a downregulation of IP3 receptors.36 The depression in IP3 generation also suggests an inhibition of phospholipase C activity by oxLDL over extended periods of time. Definitive proof of this hypothesis awaits experimental testing.

Our study also provides important evidence that IP3 receptor density is decreased in vivo in the atherosclerotic plaque. Because the IP3 pathway represents an important mechanism for controlling tension within VSMCs (via its effects on Ca2+), these defects will have important effects on vasoactivity. Our findings agree well with observations that atherosclerosis leaves arterial smooth muscle unresponsive to vasoactive agents.9 10 11 12 The present data demonstrate that cells that are in contact with oxLDL over extended periods of time exhibit an inability to elevate [Ca2+]i to a level that would support normal contractile activity. The lesions identified in IP3 signaling and Ca2+i regulation in the present study would explain the inability of atherosclerotic vessels to exhibit contractile activity in response to vasoactive agents. Our data also demonstrate that these changes in VSMC function precede any transformation in cellular morphology to the foam-cell type that is typical of an atherosclerotic plaque.

[Ca2+i] also has been suggested to play an important role in the development of atherosclerotic plaques. Excessive secretions of extracellular matrix proteins, cytokines, and chemoattractants have been associated with alterations in Ca2+i.6 7 37 Just as important, changes in gene expression, cell growth, and proliferation have been suggested to occur through changes in [Ca2+]i. Our initial studies have indicated that oxLDL is capable of inducing a release of Ca2+ from stores in proximity to the nucleus. This would suggest that oxLDL may be capable of inducing a Ca2+-mediated signal that could participate in nuclear function. Loss of such signaling may have important implications. However, this remains to be studied in detail in the future. The present data, therefore, suggest that the acute capacity of VSMCs to respond to oxLDL may represent an initial signaling response of these cells to the atherogenic environment. This may change dramatically as these cells advance in severity through the various stages of atherosclerosis, ultimately rendering the vessel hyporesponsive to a variety of vasoactive agents. OxLDL may play a key role in changing the Ca2+i regulatory mechanisms in VSMCs during this process.


*    Acknowledgments
 
This work was supported by a grant from the Medical Research Council of Canada. H. Massaeli was a Trainee of the Heart and Stroke Foundation of Canada. G.N. Pierce is a Senior Scientist of the Medical Research Council of Canada.

Received January 7, 1999; accepted July 20, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.[Medline] [Order article via Infotrieve]

2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–1792.

3. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883–3887.[Abstract/Free Full Text]

4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

5. Strickberger SA, Russek LN, Phair RD. Evidence for increased aortic plasma membrane calcium transport caused by experimental atherosclerosis in rabbits. Circ Res. 1988;62:75–80.[Abstract/Free Full Text]

6. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249–261.[Medline] [Order article via Infotrieve]

7. Phair RD. Cellular calcium and atherosclerosis: a brief review. Cell Calcium. 1988;9:275–284.[Medline] [Order article via Infotrieve]

8. Massaeli H, Pierce GN. Involvement of lipoproteins, free radicals, and calcium in cardiovascular disease processes. Cardiovasc Res. 1995;29:597–603.[Medline] [Order article via Infotrieve]

9. Yamagishi M, Nissen SE, Booth DC, Gurley JC, Koyama J, Kawano S, DeMaria AN. Coronary reactivity to nitroglycerin: intravascular ultrasound evidence for the importance of plaque distribution. J Am Coll Cardiol. 1995;25:224–230.[Abstract]

10. Berkenboom G, Unger P, Fontaine J. Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators. J Cardiovasc Pharmacol. 1989;14(suppl 11):S35–S39.

11. Ibengwe JK, Suzuki H. Changes in mechanical responses of vascular smooth muscles to acetylcholine, noradrenaline and high-potassium solution in hypercholesterolemic rabbits. Br J Pharmacol. 1986;87:395–402.[Medline] [Order article via Infotrieve]

12. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, van Hove C, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbi, I: endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res. 1986;58:552–564.[Abstract/Free Full Text]

13. Liu K, Massaeli H, Pierce GN. The action of oxidized low density lipoprotein on calcium transients in isolated rabbit cardiomyocytes. J Biol Chem. 1993;268:4145–4151.[Abstract/Free Full Text]

14. Liu K, Pierce GN. The effects of low density lipoprotein on calcium transients in isolated rabbit cardiomyocytes. J Biol Chem. 1993;268:3767–3775.[Abstract/Free Full Text]

15. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993;57:715S–724S.[Abstract/Free Full Text]

16. Milne DB, Botnen J. Retinol, {alpha}-tocopherol, lycopene, and alpha- and beta-carotene simultaneously determined in plasma by isocratic liquid chromatography. Clin Chem. 1986;32:874–876.[Abstract/Free Full Text]

17. Grünwald J, Haudenschild CC. Intimal injury in vivo activates vascular smooth muscle cell migration and explant outgrowth in vitro. Arteriosclerosis. 1984;4:183–188.[Abstract/Free Full Text]

18. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217–223.[Medline] [Order article via Infotrieve]

19. Bergmeyer HU, Bernt E. Methods of Enzymatic Analysis. New York, NY: Academic Press; 1974:579–582.

20. Massaeli H, Pierce GN. Methods for measuring sodium-hydrogen exchange in the heart. In McNeill JH, ed. Biochemical Techniques in the Heart: Methods In Pharmacology. Boca Raton, Fla: CRC Press; 1997:83–100.

21. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–3450.[Abstract/Free Full Text]

22. Benevolensky DS, Menshikova EV, Watras J, Levitsky DO, Ritov VB. Characterization of Ca2+ release from the sarcoplasmic reticulum of myocardium and vascular smooth muscle. Biomed Biochim Acta. 1987;46:S393–S398.[Medline] [Order article via Infotrieve]

23. Tanaka Y, Hata S, Ishiro H, Ishii K, Nakayama K. Quick stretch increases the production of inositol 1,4,5-trisphosphate (IP3) in porcine coronary artery. Life Sci. 1994;55:227–235.[Medline] [Order article via Infotrieve]

24. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 1983;24:1070–1076.[Abstract]

25. Lougheed M, Lum CM, Ling W, Suzuki H, Kodama T, Steinbrecher U. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem. 1997;272:12938–12944.[Abstract/Free Full Text]

26. De Smedt H., Missiaen L, Parys JB, Bootman MD, Mertens L, van Den Bosch L, Casteels R. Determination of relative amounts of inositol trisphosphate receptor mRNA isoforms by ratio polymerase chain reaction. J Biol Chem. 1994;269:21691–21698.[Abstract/Free Full Text]

27. Chen CH, Cartwright J, Li Z, Lou S, Nguyen HH, Gotto-AM J, Henry PD. Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Arterioscler Thromb Vasc Biol. 1997;17:1303–1312.[Abstract/Free Full Text]

28. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75–79.

29. van de Vijver L, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 1996;122:245–253.[Medline] [Order article via Infotrieve]

30. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1569–1576.[Abstract/Free Full Text]

31. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta. 1995;1256:141–150.[Medline] [Order article via Infotrieve]

32. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol. 1995;15:1616–1624.[Abstract/Free Full Text]

33. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.[Free Full Text]

34. Wojcikiewicz RJ, Furuichi T, Nakade S, Mikoshiba K, Nahorski SR. Muscarinic receptor activation down-regulates the type I inositol 1,4,5-trisphosphate receptor by accelerating its degradation. J Biol Chem. 1994;269:7963–7969.[Abstract/Free Full Text]

35. Sipma H, Deelman L, De Smedt H, Missiaen L, Parys JB, Vanlingen S, Henning RH, Casteels R. Agonist-induced down-regulation of type 1 and type 3 inositol 1,4,5-trisphosphate receptors in A7r5 and DDT1 MF-2 smooth muscle cells. Cell Calcium. 1998;23:11–21.[Medline] [Order article via Infotrieve]

36. Zhu CC, Furuichi T, Mikoshiba K, Wojcikiewicz RJ. Inositol 1,4,5-trisphosphate receptor down-regulation is activated directly by inositol 1,4,5-trisphosphate binding. Studies with binding-defective mutant receptors. J Biol Chem. 1999;274:3476–3484.[Abstract/Free Full Text]

37. Smirnov VN, Voyno-Yasenetskaya T, Antonov AS, Lukashev ME, Shirinsky VP, Tertov VV, Tkachuk VA. Vascular signal transduction and atherosclerosis. Ann N Y Acad Sci. 1990;598:167–181.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
R. S. Faustino, P. Cheung, M. N. Richard, E. Dibrov, A. L. Kneesch, J. F. Deniset, M. N. Chahine, K. Lee, D. Blackwood, and G. N. Pierce
Ceramide regulation of nuclear protein import
J. Lipid Res., March 1, 2008; 49(3): 654 - 662.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. P. Ander, C. Hurtado, C. S. Raposo, T. G. Maddaford, J. F. Deniset, L. V. Hryshko, G. N. Pierce, and A. Lukas
Differential sensitivities of the NCX1.1 and NCX1.3 isoforms of the Na+-Ca2+ exchanger to {alpha}-linolenic acid
Cardiovasc Res, January 15, 2007; 73(2): 395 - 403.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Zorn-Pauly, P. Schaffer, B. Pelzmann, E. Bernhart, G. Wei, P. Lang, G. Ledinski, J. Greilberger, B. Koidl, and G. Jurgens
Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity-role of lipid hydroperoxides
Cardiovasc Res, April 1, 2005; 66(1): 74 - 83.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. E. Zettler, M. A. Prociuk, J. A. Austria, G. Zhong, and G. N. Pierce
Oxidized Low-Density Lipoprotein Retards the Growth of Proliferating Cells by Inhibiting Nuclear Translocation of Cell Cycle Proteins
Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 727 - 732.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Hirono, E. Dibrov, C. Hurtado, A. Kostenuk, R. Ducas, and G. N. Pierce
Chlamydia pneumoniae Stimulates Proliferation of Vascular Smooth Muscle Cells Through Induction of Endogenous Heat Shock Protein 60
Circ. Res., October 17, 2003; 93(8): 710 - 716.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Lipskaia, M.-L. Pourci, C. Delomenie, L. Combettes, D. Goudouneche, J.-L. Paul, T. Capiod, and A.-M. Lompre
Phosphatidylinositol 3-Kinase and Calcium-Activated Transcription Pathways Are Required for VLDL-Induced Smooth Muscle Cell Proliferation
Circ. Res., May 30, 2003; 92(10): 1115 - 1122.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. E. Zettler, M. A. Prociuk, J. A. Austria, H. Massaeli, G. Zhong, and G. N. Pierce
OxLDL stimulates cell proliferation through a general induction of cell cycle proteins
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H644 - H653.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massaeli, H.
Right arrow Articles by Pierce, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massaeli, H.
Right arrow Articles by Pierce, G. N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Related Collections
Right arrow Pathophysiology
Right arrow Smooth muscle proliferation and differentiation
Right arrow Lipid and lipoprotein metabolism